Know about product usage and updates

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.

Who is the supplier of Specialty drug in India?

Indian Pharma Network (IPN) Legitimate consultant and facilitator for Specialty drugs in India. IPN, Delhi can assist you in connecting with prospective distributors, wholesalers, suppliers, and dealers of BLINCYTO (blinatumomab) for injection. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.

BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014

Related posts for product review usage

• HIGHLIGHTS OF PRESCRIBING INFORMATION
• Rationale for a Trial of Blinatumomab in MRD-Negative ALL
• Ponatinib/Blinatumomab Combo Shows Promising Efficacy and Safety in Ph+ ALL
• BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
• FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children